BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cinque A, Capasso A, Vago R, Lee MW, Floris M, Trevisani F. The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now? Biomedicines 2022;10:90. [DOI: 10.3390/biomedicines10010090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Guillaume Z, Auvray M, Vano Y, Oudard S, Helley D, Mauge L. Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies. Cancers (Basel) 2022;14. [PMID: 36551652 DOI: 10.3390/cancers14246167] [Reference Citation Analysis]
2 Shou Y, Liu Y, Xu J, Liu J, Xu T, Tong J, Liu L, Hou Y, Liu D, Yang H, Cheng G, Zhang X. TIMP1 Indicates Poor Prognosis of Renal Cell Carcinoma and Accelerates Tumorigenesis via EMT Signaling Pathway. Front Genet 2022;13:648134. [DOI: 10.3389/fgene.2022.648134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]